Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative TherapiesCompany pioneers a novel integrated drug discovery platform to advance targeted protein degradation CAMBRIDGE, Mass., October 30, 2017-- Kymera Therapeutics LLC today announced a $30M Series A Financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The company is pioneering a novel targeted protein degradation platform and approach to accelerate drug discovery and development, and deliver on its mission.